Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Prevention and risk

Topic: Risk, prevention and care in population studies

Introduction We investigate dementia risk in older adults with different disease patterns and explore the role of inflammation and apolipoprotein E (APOE) genotype. Methods A total of 2,478 dementia-free participants with two or more chronic diseases (ie, multimorbidity) part of the Swedish National study on Aging and Care in Kungsholmen (SNAC-K) were grouped according to their multimorbidity patterns and followed to detect clinical dementia. The potential modifier effect of C-reactive protein (CRP) and apolipoprotein E (APOE) genotype was tested through stratified analyses. Results People with neuropsychiatric, cardiovascular, and sensory impairment/cancer multimorbidity had increased hazards for dementia compared to the unspecific (Hazard ration (HR) 1.66, 95% confidence interval [CI] 1.13-2.42; 1.61, 95% CI 1.17-2.29; 1.32, 95% CI 1.10-1.71, respectively). Despite the lack of statistically significant interaction, high CRP increased dementia risk within these patterns, and being APOE ε4 carriers heightened dementia risk for neuropsychiatric and cardiovascular multimorbidity. Discussion Individuals with neuropsychiatric, cardiovascular, and sensory impairment/cancer patterns are at increased risk for dementia and APOE ε4, and inflammation may further increase the risk. Identifying such high-risk groups might allow tailored interventions for dementia prevention.

Key findings

Why it matters

This study found that older adults with certain patterns of multiple chronic diseases had higher dementia risk, and that inflammation and the APOE ε4 gene may further increase risk. It suggests identifying high-risk groups might allow tailored prevention, but it does not show that any intervention prevents dementia.

Study details

How this study scored 56/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 0 of 6; Still being cited 3 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 56 of 100.56 of 100 points earned44 not earned

Published in a leading specialty journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2021 — within 6 year(s) of the newest study here
Sample size 3 / 4 2,478 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 161 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 23.0 citations a year over 7 year(s) since 2021
Impact for its field and year 4 / 6 Cited 15.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 3 / 4 Cited 97 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Amaia Calderón‐Larrañaga: h-index 47 (OpenAlex, whole career)
Institution's track record 1 / 3 Karolinska Institutet: institution h-index 1,477 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 9 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 33403740)
Free to read 2 / 2 Free to read
Total 56 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Grande, G., Marengoni, A., Vetrano, D. L., Roso-Llorach, A., Rizzuto, D., Zucchelli, A., et al. (2021). Multimorbidity burden and dementia risk in older adults: The role of inflammation and genetics. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.12237

Vancouver

Grande G, Marengoni A, Vetrano DL, Roso-Llorach A, Rizzuto D, Zucchelli A, et al. Multimorbidity burden and dementia risk in older adults: The role of inflammation and genetics. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2021. doi:10.1002/alz.12237. PMID: 33403740.

BibTeX

@article{grande2021-33403740,
  author  = {Grande, G. and Marengoni, A. and Vetrano, D. L. and Roso-Llorach, A. and Rizzuto, D. and Zucchelli, A. and Qiu, C. and Fratiglioni, L. and others},
  title   = {{Multimorbidity burden and dementia risk in older adults: The role of inflammation and genetics}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2021},
  doi     = {10.1002/alz.12237},
  pmid    = {33403740},
  url     = {https://doi.org/10.1002/alz.12237}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Prevention and risk

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →